The Liquid Biopsy Company for Pets™ - PetDx®

Early Cancer Detection in Dogs with a Simple Blood Draw

PetDx® invites you to learn more about liquid biopsy technology and our OncoK9® multi-cancer early detection (MCED) test for dogs.

Scroll this page for an overview of OncoK9 and browse our Resources for PetDx medical education, research, publications, product documents, and the CANDiD Study white paper.

OncoK9 Now Also Available Through IDEXX Reference Laboratories

IDEXX Reference Laboratories

USA Test Code: 8972



Available week of January 16, 2022

To learn more about ordering,
contact your IDEXX representative

To learn more about OncoK9,
scroll this page and our resources

6 Million New Cancer Cases Per Year in Dogs

Cancer is by far the single most common cause of death in adult dogs. Like humans, dogs have a 1 in 3 lifetime risk of getting cancer, and approximately 6 million dogs are newly diagnosed with cancer each year in the United States. Older dogs, and certain predisposed breeds, are at higher risk of developing cancer. Cancer is typically diagnosed in dogs at an advanced stage, when treatment options are limited, and chances of a cure are low. Each year, cancer cuts short the lives of many dogs who might have enjoyed many healthy years with their families had the disease been detected earlier.

1 in 3 lifetime risk of getting cancer
Cancer is the cause of 30% of dog deaths
Dogs 8 and older have a higher risk of cancer
Certain breeds have a higher risk of cancer

Cancer is a Disease of the Genome

Each cell in a dog's body contains billions of DNA "letters" that make up the dog's genome. Cancer develops as a result of the successive accumulation of genomic alterations (DNA mutations) over time. All cells release DNA fragments into the bloodstream, and DNA released from cancer cells contains unique genomic alterations that can be detected by liquid biopsy technology.


Introducing OncoK9®
The Liquid Biopsy Test for Dogs™

OncoK9® enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms empowering veterinarians to provide superior care to canine patients.

Simple blood draw

Blood Draw

Most cancer tests are either invasive (like a tissue biopsy) or require special equipment (like imaging). OncoK9 requires only a simple blood draw. The sample collection can take place during the same visit when the veterinarian prescribes the test.

Multi-cancer coverage


OncoK9 has demonstrated cancer signal detection across more than 30 cancer types, including 8 of the most common cancers in dogs.

Cutting-edge technology


OncoK9 interrogates millions of cell-free DNA fragments in each blood sample, using sophisticated next-generation sequencing technology and bioinformatics algorithms to detect multiple classes of genomic alterations associated with cancer.

Early detection


By identifying cancer signal in cell-free DNA extracted from a blood sample, OncoK9 may allow for earlier detection of cancer, before the onset of clinical signs.

OncoK9 CANDiD Study

Based on next-generation sequencing (NGS) technology from Illumina that is also powering the latest advances in human liquid biopsy testing for cancer, OncoK9 has been clinically validated through the CANDiD (CANcer Detection in Dogs) Study using samples prospectively collected from over 1,000 client-owned dogs across more than 40 clinical sites on four continents. The study demonstrated the test’s ability to detect 30 canine cancer types, with overall sensitivity and specificity mirroring the performance of MCED tests recently developed for cancer screening in human patients.

Results of the CANDiD Study – the largest clinical validation study ever performed in veterinary cancer diagnostics – were recently submitted to a leading peer-reviewed journal, and a summary of the findings is available in a white paper.

How the OncoK9 Liquid Biopsy Test Works

Step 1

Step 1

A blood sample contains cell-free DNA fragments released from healthy cells and cancer cells (if cancer is present).

Step 2

Step 2

A centrifuge is used to separate the blood sample into 3 components: plasma, buffy coat, and hematocrit.

Step 3

Step 3

Cell-free DNA is extracted from plasma and an amplified DNA library is prepared for sequencing.

Step 4

Step 4

Next-generation sequencing of the DNA library generates detailed data for analysis.

Step 5

Step 5

The lab uses proprietary bioinformatics algorithms to identify cancer-associated genomic alterations.

Step 6

Step 6

A clinical report is sent to the veterinarian indicating whether or not cancer signal has been detected.

OncoK9 Intended Use

OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using next-generation sequencing (NGS) technology. OncoK9 is intended for use in dogs who are at higher risk of cancer. It is recommended as an annual screening test for all dogs starting at 8 years of age and potentially at younger ages for dogs belonging to breeds that are predisposed to cancer. It is also recommended as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings. As with any laboratory test, OncoK9 results should be interpreted by a veterinarian in the context of each patient’s medical history and clinical presentation. The test is available by prescription only.

As an oncologist, I am excited about the ways in which the OncoK9 liquid biopsy test will benefit dogs, their families, and the veterinarians that manage their care.

Andi Flory
Andi Flory, DVM, DACVIM (Oncology)
PetDx Chief Medical Officer

PetDx in the Media


 |  Publication
Multicancer detection in dogs with cell-free DNA
View Media

San Diego Union Tribune

 |  Newspaper
Dogs get cancer, too. This San Diego biotech is trying to catch canine tumors earlier
View Media


 |  Publication
PetDx Raises $62M in Series B Round
View Media


 |  Publication
PetDx raises $62 Million in Series B financing
View Media


 |  Publication
PetDx Raises $62M To Get Canine Cancer-Detecting Tech To Vets Across The US
View Media


 |  News Center
Early Cancer Detection for Dogs is Here
View Media

Veterinary Innovation Podcast

 |  Podcast
Liquid Biopsy and Early Cancer Diagnosis in Veterinary Medicine
View Media

Join the Revolution in Early Cancer Detection for Dogs

If you are eager to incorporate breakthrough innovation into your veterinary practice, we would love to partner with you. Be among the first to offer our pioneering multi-cancer early detection test to your canine patients. Provide your name and email address and we will reach out as we expand our rollout.

Email Address *

First Name *

Last Name *

Practice Name *

Position/Role *

Zip Code *

Please input numbers only

Phone Number

Please input numbers only

Lead Source


Web Form



Contact Level

* required field